NCT04666038 2025-04-20BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA
NCT01855750 2025-02-04A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaJanssen Research & Development, LLCPhase 3 Completed838 enrolled 16 charts
NCT00329030 2021-11-01BMTCTN0401National Heart, Lung, and Blood Institute (NHLBI)Phase 3 Completed224 enrolled 24 charts
NCT00486759 2017-07-25A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell LymphomaHoffmann-La RochePhase 3 Terminated787 enrolled 8 charts